MedTrace Logo

Efficacy Study of Travoprost APS Versus TRAVATAN

NCT00848536 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 371

Last updated 2012-04-06

Study results available
· View outcomes & findings →

Summary

A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension

Conditions

Interventions

DRUG

Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution

One drop once daily in the evening for 3 months

DRUG

Travoprost 0.004% (BAK-preserved) Eye Drops, Solution

One drop once daily in the evening for 3 months

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-01-31
Completion
2010-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00848536 on ClinicalTrials.gov